All In Biotech

NDA 215422 · Strides Pharma Intl

Lyvispah

Baclofen · Oral · gamma-Aminobutyric Acid-ergic Agonist

Last checked: Nov 19, 2026Latest source record: Nov 22, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Nov 22, 2021

Approved uses

1

Original approval plus efficacy supplements

Registered trials

123

30 Phase 3, 6 recruiting

FAERS reports

85,244

56,383 serious, 6,379 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 22, 2026.

LYVISPAH is indicated for the treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. LYVISPAH may also be of some value in patients with spinal cord injuries and other spinal cord diseases. Limitations of Use LYVISPAH is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. LYVISPAH is a gamma-aminobutyric acid (GABA-ergic) agonist indicated for the treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. ( 1 ) LYVISPAH may also be of some value in patient with spinal cord injuries and other spinal cord diseases. ( 1 ) Limitations of Use LYVISPAH is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. ( 1 )

Mechanism: The precise mechanism of action of baclofen is not fully understood. Baclofen inhibits both monosynaptic and polysynaptic reflexes at the spinal level, possibly by decreasing excitatory neurotransmitter release from afferent terminals, although actions at supraspinal sites may also occur and contribute to its clinical effect. Baclofen is a structural analog of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), and may exert its effects by stimulation of the GABA-B receptor subtype .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • LYVISPAH · BACLOFEN 10MG/PACKET · GRANULE, ORAL · Prescription
  • LYVISPAH · BACLOFEN 20MG/PACKET · GRANULE, ORAL · Discontinued
  • LYVISPAH · BACLOFEN 5MG/PACKET · GRANULE, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Baclofen" as an intervention, any sponsor and status, largest first.

All 123 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue6,301
  • drug ineffective5,647
  • pain5,556
  • fall5,450
  • nausea4,694
  • headache4,446
  • gait disturbance4,135
  • off label use3,870
  • dizziness3,632
  • urinary tract infection3,527
  • asthenia3,445
  • multiple sclerosis relapse3,420

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004646
2005757
2006675
2007795
2008886
20091,033
20101,500
20111,738
20122,502
20133,001
20144,251
20155,157
20167,596
20177,023
20187,705
20196,672
20205,778
20215,486
20225,099
20235,673
20244,227
20254,066
20262,975

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lyvispah (Baclofen)

2024 spending

$163K

Beneficiaries

315

846 claims

Per beneficiary

$518

$3.69 per unit

View as table
YearSpending
2020$0
2021$0
2022$111,974
2023$143,986
2024$163,041

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 558 on PubMed

Sponsor: Strides Pharma Intl

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.